AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10651074 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha2a (3 million units subcutaneously, twice a week for 3 months)
Number of subjects: 22
Study 10651074 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha2a
Number of subjects: 22
Study 10651074 — intervention group
Group type: COMPARATOR
Intervention: Control group (15 age- and sex-matched healthy adults)
Number of subjects: 22
Study 8754409 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic glomerulonephritis without nephrotic syndrome (NS)
Number of subjects: 60
Study 8754409 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic glomerulonephritis with nephrotic syndrome (NS)
Number of subjects: 60
Study 8754409 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients showing SPA
Number of subjects: 60
Study 8754409 — intervention group
Group type: COMPARATOR
Intervention: Patients with CGN and CGN+NS
Number of subjects: 60
Study 8754409 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with SPA
Number of subjects: 60
Study 1845847 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 100 mg/m2 IV day 1 and etoposide 120 mg/m2 IV days 1, 2, and 3
Number of subjects: 83
Study 1845847 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin 100 mg/m2 IV day 1 and etoposide 120 mg/m2 IV day 1 and 240 mg/m2 orally days 2 and 3
Number of subjects: 83
Study 1845847 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 83
Study 1845847 — intervention group
Group type: EXPERIMENTAL
Intervention: IV etoposide regimen
Number of subjects: 83
Study 6353336 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazoline (500 mg intramuscular every 8 hours for 6 doses)
Number of subjects: 91
Study 6353336 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole (800 mg sulfametoxazole and 160 mg trimetoprime intramuscular every 12 hours for 6 doses)
Number of subjects: 91
Study 6353336 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antibiotics)
Number of subjects: 91
Study 30777064 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy (MT) and stabilizing exercises (SEs)
Number of subjects: 60
Study 30777064 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilizing exercises (SEs)
Number of subjects: 60
Study 30777064 — intervention group
Group type: COMPARATOR
Intervention: Home exercises
Number of subjects: 60
Study 29055680 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 IU intranasal OXT
Number of subjects: 40
Study 29055680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 25845530 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-based HIV prevention intervention
Number of subjects: 227
Study 25845530 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 227
Study 23890374 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented milk containing Lactobacillus casei strain Shirota (LcS)
Number of subjects: 154
Study 23890374 — intervention group
Group type: COMPARATOR
Intervention: Placebo drinks
Number of subjects: 154
Study 21489741 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing integrated with social network counseling
Number of subjects: 28
Study 21489741 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 28
Study 19035970 — intervention group
Group type: EXPERIMENTAL
Intervention: Prucalopride 2 mg
Number of subjects: 641
Study 19035970 — intervention group
Group type: EXPERIMENTAL
Intervention: Prucalopride 4 mg
Number of subjects: 641
Study 19035970 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 641
Study 19035970 — intervention group
Group type: EXPERIMENTAL
Intervention: Prucalopride
Number of subjects: 641
Study 17341781 — intervention group
Group type: EXPERIMENTAL
Intervention: GuardWire distal protection device during PCI
Number of subjects: 0
Study 17341781 — intervention group
Group type: COMPARATOR
Intervention: PCI without distal protection (Control)
Number of subjects: 0
Study 15899441 — intervention group
Group type: EXPERIMENTAL
Intervention: Artisan phakic intraocular lens (IOL) implantation
Number of subjects: 87
Study 15899441 — intervention group
Group type: COMPARATOR
Intervention: Crystalline lens rise measurement
Number of subjects: 87
Study 15899441 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystalline lens rise as a safety criterion
Number of subjects: 87
Study 11912561 — intervention group
Group type: EXPERIMENTAL
Intervention: Psyllium (15 g PSY/d)
Number of subjects: 68
Study 11912561 — intervention group
Group type: COMPARATOR
Intervention: Control (cookies)
Number of subjects: 68
Study 9698665 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplementation
Number of subjects: 69
Study 9698665 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium plus vitamins A, C, and E
Number of subjects: 69
Study 9698665 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 8880382 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular and intralesional beta-interferon treatment
Number of subjects: 49
Study 8880382 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular beta-interferon treatment
Number of subjects: 49
Study 8880382 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional beta-interferon treatment
Number of subjects: 49
Study 8880382 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 49
Study 2114628 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrin (75 mg acute administration)
Number of subjects: 26
Study 2114628 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrin (3 x 25 mg for 6 months)
Number of subjects: 26
Study 2114628 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrin (75 mg additional administration)
Number of subjects: 26
Study 2114628 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 26
Study 376578 — intervention group
Group type: EXPERIMENTAL
Intervention: Gerovital
Number of subjects: 25
Study 376578 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 31097067 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-resistant tuberculosis (DR-TB) patients
Number of subjects: 900
Study 31097067 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 900
Study 31097067 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased BMI
Number of subjects: 900
Study 31097067 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Mellitus (DM)
Number of subjects: 900
Study 31097067 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 900
Study 31097067 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD risk score
Number of subjects: 900
Study 28103819 — intervention group
Group type: EXPERIMENTAL
Intervention: Telbivudine (600 mg/day)
Number of subjects: 97
Study 28103819 — intervention group
Group type: COMPARATOR
Intervention: Entecavir (0.5 mg/day)
Number of subjects: 97
Study 26016867 — intervention group
Group type: EXPERIMENTAL
Intervention: Krill and salmon oil (KS oil), 5 1-g capsules for 8 weeks
Number of subjects: 47
Study 26016867 — intervention group
Group type: COMPARATOR
Intervention: Control (canola oil), 5 1-g capsules for 8 weeks
Number of subjects: 47
Study 26016867 — intervention group
Group type: EXPERIMENTAL
Intervention: Krill and salmon oil (KS oil) after controlling for blood EPA and DHA levels
Number of subjects: 47
Study 23287748 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromagnetic (EM) navigationally assisted insertion without fluoroscopy (SureShot; Smith & Nephew)
Number of subjects: 101
Study 23287748 — intervention group
Group type: COMPARATOR
Intervention: Standard fluoroscopic assistance (OEC 9900; G.E. HealthCare)
Number of subjects: 101
Study 23287748 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (EM and fluoroscopic)
Number of subjects: 101
Study 20926968 — intervention group
Group type: EXPERIMENTAL
Intervention: 100-m time trial (TT)
Number of subjects: 10
Study 20926968 — intervention group
Group type: EXPERIMENTAL
Intervention: 400-m time trial (TT)
Number of subjects: 10
Study 20926968 — intervention group
Group type: EXPERIMENTAL
Intervention: 200-m time trial (TT)
Number of subjects: 10
Study 20926968 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart Rate (HR)
Number of subjects: 10
Study 20926968 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate of Perceived Dyspnea (RPD)
Number of subjects: 10
Study 19363873 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical retinoids (e.g., adapalene, tazarotene)
Number of subjects: 0
Study 19363873 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (topical retinoids with benzoyl peroxide and/or antibiotics and/or hormonal therapy)
Number of subjects: 0
Study 19363873 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical retinoid monotherapy
Number of subjects: 0
Study 19363873 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-combination products (topical retinoid/antimicrobial therapy)
Number of subjects: 0
Study 17547537 — intervention group
Group type: EXPERIMENTAL
Intervention: teriparatide (20 microg/d)
Number of subjects: 65
Study 15650348 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 0
Study 11562516 — intervention group
Group type: COMPARATOR
Intervention: Nitrogen dioxide (NO2) exposure (1.5 parts per million) for 20 minutes
Number of subjects: 30
Study 11562516 — intervention group
Group type: COMPARATOR
Intervention: Ascorbic acid supplementation (500 mg twice daily) for 2 weeks
Number of subjects: 30
Study 9506196 — intervention group
Group type: EXPERIMENTAL
Intervention: ADCON-L gel
Number of subjects: 298
Study 9506196 — intervention group
Group type: COMPARATOR
Intervention: Control group (nothing)
Number of subjects: 298
Study 7821003 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium dichromate (2.5 mg)
Number of subjects: 30
Study 7821003 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 3133250 — intervention group
Group type: EXPERIMENTAL
Intervention: hMG (human menopausal gonadotropin)
Number of subjects: 40
Study 3133250 — intervention group
Group type: COMPARATOR
Intervention: hFSH (human follicle-stimulating hormone)
Number of subjects: 40
Study 4943605 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofibrate
Number of subjects: 497
Study 4943605 — intervention group
Group type: COMPARATOR
Intervention: Corn oil (control)
Number of subjects: 497
Study 30942033 — intervention group
Group type: EXPERIMENTAL
Intervention: Thumb-tack acupuncture with surrounding needling method plus medication (oral valaciclovir hydrochloride, mecobalamin, vitamin B1)
Number of subjects: 60
Study 30942033 — intervention group
Group type: COMPARATOR
Intervention: Medication alone (oral valaciclovir hydrochloride, mecobalamin, vitamin B1)
Number of subjects: 60
Study 30942033 — intervention group
Group type: EXPERIMENTAL
Intervention: Thumb-tack acupuncture with surrounding needling method plus medication
Number of subjects: 60
Study 30942033 — intervention group
Group type: COMPARATOR
Intervention: Medication alone
Number of subjects: 60
Study 28197716 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow Release Insemination (SRI)
Number of subjects: 50
Study 28197716 — intervention group
Group type: COMPARATOR
Intervention: Standard Bolus IUI
Number of subjects: 50
Study 28197716 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analysis of SRI
Number of subjects: 50
Study 25770758 — intervention group
Group type: EXPERIMENTAL
Intervention: High Dairy condition (+4 servings/day of conventional non-fat dairy products)
Number of subjects: 49
Study 25770758 — intervention group
Group type: COMPARATOR
Intervention: No Dairy condition (+4 servings/day fruit products)
Number of subjects: 49
Study 23537477 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance use disorder (SUD) patients at 6 months follow-up
Number of subjects: 323
Study 23537477 — intervention group
Group type: EXPERIMENTAL
Intervention: SUD patients with ongoing substance use at follow-up
Number of subjects: 323
Study 23537477 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with onset of SUD before age 16
Number of subjects: 323
Study 23537477 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher frequency of cannabis consumption
Number of subjects: 323
Study 23537477 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis use duration
Number of subjects: 323
Study 23537477 — intervention group
Group type: COMPARATOR
Intervention: FE-SUD and FE-non-SUD
Number of subjects: 323
Study 21552059 — intervention group
Group type: COMPARATOR
Intervention: Circular stapler
Number of subjects: 198
Study 21552059 — intervention group
Group type: EXPERIMENTAL
Intervention: Contour-curved stapler
Number of subjects: 198
Study 21552059 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 198
Study 19192991 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol 600 microg
Number of subjects: 51
Study 19192991 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol 300 microg
Number of subjects: 51
Study 19192991 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol 150 microg
Number of subjects: 51
Study 19192991 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 12 microg
Number of subjects: 51
Study 19192991 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 16963194 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-compliant women
Number of subjects: 469
Study 16963194 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for non-attendance
Number of subjects: 469
Study 16963194 — intervention group
Group type: EXPERIMENTAL
Intervention: Hurdles faced by willing women
Number of subjects: 469
Study 14530858 — intervention group
Group type: EXPERIMENTAL
Intervention: NEXAP0 (pressure equal to IAP)
Number of subjects: 30
Study 14530858 — intervention group
Group type: EXPERIMENTAL
Intervention: NEXAP-5 (5 cmH(2)O more negative than NEXAP0)
Number of subjects: 30
Study 14530858 — intervention group
Group type: EXPERIMENTAL
Intervention: NEXAP-10 (10 cmH(2)O more negative than NEXAP0)
Number of subjects: 30
Study 14530858 — intervention group
Group type: EXPERIMENTAL
Intervention: NEXAP-10
Number of subjects: 30
Study 10757255 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine (titrated to a maximum of 150 mg/day)
Number of subjects: 116
Study 10757255 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline (titrated to a maximum of 150 mg/day)
Number of subjects: 116
Study 8841216 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy
Number of subjects: 109
Study 8841216 — intervention group
Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 109
Study 8841216 — intervention group
Group type: EXPERIMENTAL
Intervention: Both procedures
Number of subjects: 109
Study 1419551 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin (200 mg od)
Number of subjects: 1069
Study 1419551 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim (200 mg bd)
Number of subjects: 1069
Study 1419551 — intervention group
Group type: COMPARATOR
Intervention: Co-trimoxazole (trimethoprim 160 mg and sulphamethoxazole 800 mg bd)
Number of subjects: 1069
Study 1419551 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin
Number of subjects: 1069
Study 1419551 — intervention group
Group type: COMPARATOR
Intervention: Co-trimoxazole
Number of subjects: 1069
Study 1419551 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim
Number of subjects: 1069
Study 6362695 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine (2 and 3 ml)
Number of subjects: 40
Study 6362695 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% amethocaine (2 and 3 ml)
Number of subjects: 40
Study 29058057 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate
Number of subjects: 0
Study 29058057 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate
Number of subjects: 0
Study 27231088 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient emotional status
Number of subjects: 299
Study 27231088 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient physical and emotional status
Number of subjects: 299
Study 27231088 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver mood state at baseline
Number of subjects: 299
Study 24845181 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan (Trp) supplementation for seven days
Number of subjects: 118
Study 24845181 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLC) intake for seven days
Number of subjects: 118
Study 22289248 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized exercise tolerance testing (ETT) protocol based on habitual gait speed (HGS)
Number of subjects: 141
Study 20486336 — intervention group
Group type: EXPERIMENTAL
Intervention: PureZone, a combination therapy involving localized air filtration and pillow encasement
Number of subjects: 35
Study 20486336 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 19145998 — intervention group
Group type: EXPERIMENTAL
Intervention: levo-bupivacaine
Number of subjects: 112
Study 19145998 — intervention group
Group type: COMPARATOR
Intervention: lidocaine
Number of subjects: 112
Study 11574360 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg/kg ketamine
Number of subjects: 20
Study 11574360 — intervention group
Group type: COMPARATOR
Intervention: 2.5 mg/kg propofol
Number of subjects: 20
Study 9041875 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n = 540) received individualized dietary counseling to reduce saturated fat and cholesterol intake.
Number of subjects: 1062
Study 9041875 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 522) received brief dietary counseling according to current practice.
Number of subjects: 1062
Study 9041875 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n = 540)
Number of subjects: 1062
Study 9041875 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 1062
Study 7939487 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 40
Study 7939487 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 40
Study 7939487 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepines (most often prescribed)
Number of subjects: 40
Study 7939487 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive psychotherapy (in combination with benzodiazepines)
Number of subjects: 40
Study 7939487 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 3148941 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms/day selenium for 3 weeks
Number of subjects: 18
Study 3148941 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 micrograms selenium per oral administration after two hours of hard training
Number of subjects: 18
Study 3148941 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 weeks
Number of subjects: 18
Study 3148941 — intervention group
Group type: COMPARATOR
Intervention: Placebo after two hours of hard training
Number of subjects: 18
Study 31868656 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild electrostimulation using the BodyFlow device for three weeks, five times a day for 20 minutes along with the standard rehabilitation protocol.
Number of subjects: 93
Study 31868656 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation protocol after knee arthroscopy (Control group).
Number of subjects: 93
Study 30507604 — intervention group
Group type: EXPERIMENTAL
Intervention: Organ dose modulation with ASiR-V algorithm
Number of subjects: 300
Study 30507604 — intervention group
Group type: COMPARATOR
Intervention: 3D smart mA modulation
Number of subjects: 300
Study 28737262 — intervention group
Group type: EXPERIMENTAL
Intervention: 7% hypertonic saline (HS) inhaled for 8 hours overnight using the tPAD system
Number of subjects: 12
Study 28737262 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (nasal cannula without aerosol)
Number of subjects: 12
Study 28737262 — intervention group
Group type: EXPERIMENTAL
Intervention: 7% hypertonic saline (HS) inhaled
Number of subjects: 12
Study 25310142 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 76
Study 25310142 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy
Number of subjects: 76
Study 25310142 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of CBT and pharmacotherapy
Number of subjects: 76
Study 25310142 — intervention group
Group type: COMPARATOR
Intervention: Placebo pill
Number of subjects: 76
Study 23204506 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin matrix (PRFM)
Number of subjects: 60
Study 23204506 — intervention group
Group type: COMPARATOR
Intervention: Control (no PRFM)
Number of subjects: 60
Study 21480491 — intervention group
Group type: EXPERIMENTAL
Intervention: VTE risk stratification model
Number of subjects: 242738
Study 18615232 — intervention group
Group type: EXPERIMENTAL
Intervention: Total leg lean mass (TLM)
Number of subjects: 57
Study 18615232 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced muscle strength
Number of subjects: 57
Study 18615232 — intervention group
Group type: COMPARATOR
Intervention: Gender
Number of subjects: 57
Study 18615232 — intervention group
Group type: EXPERIMENTAL
Intervention: TLM and muscle strength correlation
Number of subjects: 57
Study 16837882 — intervention group
Group type: EXPERIMENTAL
Intervention: letrozole 2.5 mg/day
Number of subjects: 61
Study 16837882 — intervention group
Group type: COMPARATOR
Intervention: placebo tablet
Number of subjects: 61
Study 12625886 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who received a copy of their GP letter
Number of subjects: 200
Study 12625886 — intervention group
Group type: COMPARATOR
Intervention: Patients who did not receive a copy of their GP letter
Number of subjects: 200
Study 10857519 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistive inspiratory muscle training (RIMT) for 15 to 20 minutes per session, twice per day, 7 days a week for 6 weeks.
Number of subjects: 20
Study 10857519 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided).
Number of subjects: 20
Study 9663827 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth carbomer foam enemas (270 mg elemental bismuth)
Number of subjects: 40
Study 9663827 — intervention group
Group type: COMPARATOR
Intervention: Placebo foam enemas
Number of subjects: 40
Study 8193880 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime with or without Tobramycin (C +/‐ T)
Number of subjects: 205